Do analysts prefer SONX or VRAX?

Virax Biolabs Group has a consensus target price of $25.00, suggesting a potential upside of 1,415.15%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Sonendo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, SONX or VRAX?

Virax Biolabs Group has lower revenue, but higher earnings than Sonendo. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sonendo $44.40M 0.14 -$60.92M -$71.12 N/A Virax Biolabs Group $10K 132.00 -$5.02M N/A N/A

Do analysts rate VRAX or NVNO?

Virax Biolabs Group presently has a consensus target price of $25.00, suggesting a potential upside of 1,415.15%. Given Virax Biolabs Group's higher probable upside, equities research analysts plainly believe Virax Biolabs Group is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has stronger valuation & earnings, VRAX or NVNO?

Virax Biolabs Group has higher revenue and earnings than enVVeno Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 132.00 -$5.02M N/A N/A enVVeno Medical N/A N/A -$19.47M -$19.33 N/A

Is VRAX or NVNO more profitable?

Virax Biolabs Group's return on equity of 0.00% beat enVVeno Medical's return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A enVVeno Medical N/A -62.28% -56.83%

Do analysts rate INBS or VRAX?

Virax Biolabs Group has a consensus price target of $25.00, indicating a potential upside of 1,415.15%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than Intelligent Bio Solutions. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intelligent Bio Solutions 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, INBS or VRAX?

Virax Biolabs Group has lower revenue, but higher earnings than Intelligent Bio Solutions. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intelligent Bio Solutions $4.22M 1.14 -$12.43M -$9.02 N/A Virax Biolabs Group $10K 132.00 -$5.02M N/A N/A

Which has higher valuation & earnings, VRAX or MBAI?

MBody AI has lower revenue, but higher earnings than Virax Biolabs Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 132.00 -$5.02M N/A N/A MBody AI N/A N/A $4.14M -$7.42 N/A

Is VRAX or MBAI more profitable?

Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A MBody AI N/A N/A N/A

Does the media favor VRAX or MBAI?

In the previous week, Virax Biolabs Group had 2 more articles in the media than MBody AI. MarketBeat recorded 4 mentions for Virax Biolabs Group and 2 mentions for MBody AI. Virax Biolabs Group's average media sentiment score of 0.72 beat MBody AI's score of 0.61 indicating that Virax Biolabs Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virax Biolabs Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MBody AI 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, VRAX or ICCM?

Virax Biolabs Group has higher earnings, but lower revenue than IceCure Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 132.00 -$5.02M N/A N/A IceCure Medical $3.38M 1.06 -$15.06M -$8.52 N/A

Does the media favor VRAX or ICCM?

In the previous week, Virax Biolabs Group and Virax Biolabs Group both had 4 articles in the media. IceCure Medical's average media sentiment score of 1.20 beat Virax Biolabs Group's score of 0.72 indicating that IceCure Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virax Biolabs Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive IceCure Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Virax Biolabs Group (VRAX) Competitors

$1.65 -0.09 (-5.07%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$1.67 +0.02 (+1.15%)

As of 08:14 AM Eastern

Compare

VRAX vs. SONX, NVNO, INBS, MBAI, and ICCM

Should you buy Virax Biolabs Group stock or one of its competitors? Virax Biolabs Group's main competitors and comparable companies include Sonendo (SONX), enVVeno Medical (NVNO), Intelligent Bio Solutions (INBS), MBody AI (MBAI), and IceCure Medical (ICCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Virax Biolabs Group compare to Sonendo?

Sonendo (NYSE:SONX) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Virax Biolabs Group has lower revenue, but higher earnings than Sonendo.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonendo	$44.40M	0.14	-$60.92M	-$71.12	N/A
Virax Biolabs Group	$10K	132.00	-$5.02M	N/A	N/A

Sonendo has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

28.7% of Sonendo shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 7.9% of Sonendo shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Virax Biolabs Group has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Virax Biolabs Group's return on equity of 0.00% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonendo	-92.74%	-184.01%	-68.60%
Virax Biolabs Group	N/A	N/A	N/A

Virax Biolabs Group has a consensus target price of $25.00, suggesting a potential upside of 1,415.15%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Virax Biolabs Group had 4 more articles in the media than Sonendo. MarketBeat recorded 4 mentions for Virax Biolabs Group and 0 mentions for Sonendo. Virax Biolabs Group's average media sentiment score of 0.72 beat Sonendo's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonendo	Neutral
Virax Biolabs Group	Positive

Summary

Virax Biolabs Group beats Sonendo on 11 of the 14 factors compared between the two stocks.

How does Virax Biolabs Group compare to enVVeno Medical?

Virax Biolabs Group (NASDAQ:VRAX) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Virax Biolabs Group presently has a consensus target price of $25.00, suggesting a potential upside of 1,415.15%. Given Virax Biolabs Group's higher probable upside, equities research analysts plainly believe Virax Biolabs Group is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Virax Biolabs Group has higher revenue and earnings than enVVeno Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	132.00	-$5.02M	N/A	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

Virax Biolabs Group has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Virax Biolabs Group's return on equity of 0.00% beat enVVeno Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
enVVeno Medical	N/A	-62.28%	-56.83%

In the previous week, Virax Biolabs Group had 3 more articles in the media than enVVeno Medical. MarketBeat recorded 4 mentions for Virax Biolabs Group and 1 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 1.79 beat Virax Biolabs Group's score of 0.72 indicating that enVVeno Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Virax Biolabs Group	Positive
enVVeno Medical	Very Positive

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 15.0% of enVVeno Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Virax Biolabs Group beats enVVeno Medical on 9 of the 13 factors compared between the two stocks.

How does Virax Biolabs Group compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Virax Biolabs Group has a consensus price target of $25.00, indicating a potential upside of 1,415.15%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than Intelligent Bio Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virax Biolabs Group has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -294.88%. Virax Biolabs Group's return on equity of 0.00% beat Intelligent Bio Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-294.88%	-175.35%	-91.25%
Virax Biolabs Group	N/A	N/A	N/A

In the previous week, Virax Biolabs Group had 2 more articles in the media than Intelligent Bio Solutions. MarketBeat recorded 4 mentions for Virax Biolabs Group and 2 mentions for Intelligent Bio Solutions. Intelligent Bio Solutions' average media sentiment score of 1.45 beat Virax Biolabs Group's score of 0.72 indicating that Intelligent Bio Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
Intelligent Bio Solutions	Positive
Virax Biolabs Group	Positive

Virax Biolabs Group has lower revenue, but higher earnings than Intelligent Bio Solutions.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$4.22M	1.14	-$12.43M	-$9.02	N/A
Virax Biolabs Group	$10K	132.00	-$5.02M	N/A	N/A

Intelligent Bio Solutions has a beta of 4.31, indicating that its share price is 331% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Summary

Virax Biolabs Group beats Intelligent Bio Solutions on 10 of the 14 factors compared between the two stocks.

How does Virax Biolabs Group compare to MBody AI?

Virax Biolabs Group (NASDAQ:VRAX) and MBody AI (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

MBody AI has lower revenue, but higher earnings than Virax Biolabs Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	132.00	-$5.02M	N/A	N/A
MBody AI	N/A	N/A	$4.14M	-$7.42	N/A

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
MBody AI	N/A	N/A	N/A

In the previous week, Virax Biolabs Group had 2 more articles in the media than MBody AI. MarketBeat recorded 4 mentions for Virax Biolabs Group and 2 mentions for MBody AI. Virax Biolabs Group's average media sentiment score of 0.72 beat MBody AI's score of 0.61 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Virax Biolabs Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MBody AI	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 1.1% of MBody AI shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 0.5% of MBody AI shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Virax Biolabs Group has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, MBody AI has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Virax Biolabs Group currently has a consensus target price of $25.00, indicating a potential upside of 1,415.15%. MBody AI has a consensus target price of $10.00, indicating a potential upside of 227.87%. Given Virax Biolabs Group's higher probable upside, research analysts plainly believe Virax Biolabs Group is more favorable than MBody AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MBody AI	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Virax Biolabs Group beats MBody AI on 7 of the 8 factors compared between the two stocks.

How does Virax Biolabs Group compare to IceCure Medical?

Virax Biolabs Group (NASDAQ:VRAX) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Virax Biolabs Group has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. Virax Biolabs Group's return on equity of 0.00% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
IceCure Medical	-427.67%	-174.26%	-112.58%

In the previous week, Virax Biolabs Group and Virax Biolabs Group both had 4 articles in the media. IceCure Medical's average media sentiment score of 1.20 beat Virax Biolabs Group's score of 0.72 indicating that IceCure Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Virax Biolabs Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
IceCure Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Virax Biolabs Group has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Virax Biolabs Group presently has a consensus target price of $25.00, suggesting a potential upside of 1,415.15%. IceCure Medical has a consensus target price of $30.00, suggesting a potential upside of 2,784.62%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Virax Biolabs Group has higher earnings, but lower revenue than IceCure Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	132.00	-$5.02M	N/A	N/A
IceCure Medical	$3.38M	1.06	-$15.06M	-$8.52	N/A

Summary

Virax Biolabs Group beats IceCure Medical on 8 of the 13 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRAX vs. The Competition

Export

Metric	Virax Biolabs Group	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.39M	$5.59B	$7.19B	$13.18B
Dividend Yield	N/A	1.74%	2.52%	19.59%
P/E Ratio	N/A	21.32	223.62	21.16
Price / Sales	132.00	65.09	547.34	66.59
Price / Cash	N/A	32.11	76.68	52.75
Price / Book	0.04	5.72	10.22	5.92
Net Income	-$5.02M	$146.93M	$3.50B	$380.90M
7 Day Performance	-17.09%	-1.61%	-3.50%	-3.90%
1 Month Performance	-36.29%	-4.38%	-7.78%	-6.42%
1 Year Performance	-89.69%	0.69%	0.79%	-6.02%

Virax Biolabs Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRAX Virax Biolabs Group	2.7387 of 5 stars	$1.65 -5.1%	$25.00 +1,415.2%	-90.0%	$1.39M	$10K	N/A	26
SONX Sonendo	N/A	$1.28 +28.0%	N/A	N/A	$6.11M	$44.40M	N/A	250
NVNO enVVeno Medical	1.5306 of 5 stars	$8.17 -0.4%	N/A	-72.9%	$5.70M	N/A	N/A	33	Positive News
INBS Intelligent Bio Solutions	1.3885 of 5 stars	$1.59 +0.6%	N/A	-86.6%	$5.24M	$4.22M	N/A	10	Positive News Short Interest Decrease Gap Up
MBAI MBody AI	2.6512 of 5 stars	$3.21 -0.9%	$10.00 +211.5%	N/A	$4.46M	N/A	N/A	85	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRAX) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virax Biolabs Group (VRAX) Competitors

VRAX vs. SONX, NVNO, INBS, MBAI, and ICCM

How does Virax Biolabs Group compare to Sonendo?

Summary

How does Virax Biolabs Group compare to enVVeno Medical?

Summary

How does Virax Biolabs Group compare to Intelligent Bio Solutions?

Summary

How does Virax Biolabs Group compare to MBody AI?

Summary

How does Virax Biolabs Group compare to IceCure Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virax Biolabs Group (VRAX) Competitors

VRAX vs. SONX, NVNO, INBS, MBAI, and ICCM

How does Virax Biolabs Group compare to Sonendo?

Which has stronger earnings and valuation, SONX or VRAX?

Which has more risk and volatility, SONX or VRAX?

Do institutionals and insiders have more ownership in SONX or VRAX?

Is SONX or VRAX more profitable?

Do analysts prefer SONX or VRAX?

Does the media refer more to SONX or VRAX?

Summary

How does Virax Biolabs Group compare to enVVeno Medical?

Do analysts rate VRAX or NVNO?

Which has stronger valuation & earnings, VRAX or NVNO?

Which has more risk & volatility, VRAX or NVNO?

Is VRAX or NVNO more profitable?

Does the media favor VRAX or NVNO?

Do insiders & institutionals hold more shares of VRAX or NVNO?

Summary

How does Virax Biolabs Group compare to Intelligent Bio Solutions?

Do institutionals and insiders believe in INBS or VRAX?

Do analysts rate INBS or VRAX?

Is INBS or VRAX more profitable?

Does the media refer more to INBS or VRAX?

Which has preferable valuation and earnings, INBS or VRAX?

Which has more volatility & risk, INBS or VRAX?

Summary

How does Virax Biolabs Group compare to MBody AI?

Which has higher valuation & earnings, VRAX or MBAI?

Is VRAX or MBAI more profitable?

Does the media favor VRAX or MBAI?

Do insiders and institutionals have more ownership in VRAX or MBAI?

Which has more risk and volatility, VRAX or MBAI?

Do analysts rate VRAX or MBAI?

Summary

How does Virax Biolabs Group compare to IceCure Medical?

Is VRAX or ICCM more profitable?

Does the media favor VRAX or ICCM?

Which has more risk & volatility, VRAX or ICCM?

Do analysts prefer VRAX or ICCM?

Do insiders and institutionals hold more shares of VRAX or ICCM?

Which has stronger valuation and earnings, VRAX or ICCM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools